Device Trial Radar · NCT07184528
PATCHVALVE: Endobronchial Valves Plus Blood Patch for Persistent Air Leaks
Last checked: Nov 20, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Jul 1, 2025
Primary completion
Jul 1, 2026
Study completion Jul 1, 2027
Sponsor
- Lead sponsor
- Beth Israel Deaconess Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 22, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to evaluate the real-world safety and effectiveness of combining endobronchial valve (IBV) placement with endobronchial blood patching (EBP) for the treatment of persistent air leaks (PALs) in adult patients undergoing bronchoscopy. PALs are a challenging condition often associated with prolonged hospital stays, increased morbidity, and delayed recovery. The main questions this study aims to answer are: * Does the combination of endobronchial valve placement and endobronchial blood patching accelerate resolution of persistent air leaks? * What are the procedural outcomes, complications, and hospital-related metrics (e.g., chest tube duration, length of stay, and readmission rates) associated with this technique? Participants will: * Undergo standard-of-care bronchoscopy with identification of air leak source. * Receive intrabronchial instillation of autologous blood and tranexamic acid (TXA) followed by balloon occlusion and endobronchial valve placement. * Be followed for resolution of air leak and post-procedure outcomes through standard inpatient monitoring and data collection.
Conditions
- Persistent Air Leaks
Interventions
Endobronchial Blood PatchDevice
This component of the procedure involves sealing persistent air leak (PAL) defects using autologous blood delivered via a balloon catheter. After identifying the target segment, carefully noting the airway angle and distal carina, a sizing balloon is deployed and inflated to ensure a tight seal. Under anesthesia, 30 mL of fresh blood is prepared and infused into the target airway until either visible extravasation occurs or the full volume is delivered. Following this, up to 10 mL of tranexamic acid (TXA) may be administered, again until extravasation occurs or the volume is fully instilled. The balloon remains inflated for 3-5 minutes after the instillation to allow clot formation and sealing of the defect.
Spiration Valve System (SVS) PlacementDevice
Once the blood patch component is complete and the balloon is deflated, a Spiration Valve System (SVS) is placed proximally in the airway. The valve acts as a one-way device that decompresses the targeted lung segment while stabilizing the clot created by the blood patch. This supports durable resolution of the air leak, particularly in cases where collateral ventilation might otherwise reduce the efficacy of valve therapy alone.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events Following Combined Blood Patch and Spiration Valve ApplicationTime frame: From enrollment to the end of the observational period at 12 months post-intervention as per standard procedure
- Feasibility of Combined Endobronchial Blood Patch and Spiration Valve ProcedureTime frame: From enrollment to end of procedure.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beth Isreal Deaconess Medical Center
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.